Harbor Advisors LLC Sells 795 Shares of Kenvue Inc. (NYSE:KVUE)

Harbor Advisors LLC trimmed its position in Kenvue Inc. (NYSE:KVUE) by 2.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,950 shares of the company’s stock after selling 795 shares during the period. Harbor Advisors LLC’s holdings in Kenvue were worth $575,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. FMR LLC increased its position in Kenvue by 2.3% in the 3rd quarter. FMR LLC now owns 137,915,493 shares of the company’s stock valued at $3,189,985,000 after buying an additional 3,075,019 shares in the last quarter. State Street Corp increased its position in Kenvue by 16.8% in the 3rd quarter. State Street Corp now owns 127,213,940 shares of the company’s stock valued at $2,942,458,000 after buying an additional 18,283,473 shares in the last quarter. Geode Capital Management LLC increased its position in Kenvue by 0.9% in the 3rd quarter. Geode Capital Management LLC now owns 44,677,077 shares of the company’s stock valued at $1,029,810,000 after buying an additional 399,846 shares in the last quarter. Harris Associates L P boosted its stake in Kenvue by 7.5% during the 3rd quarter. Harris Associates L P now owns 31,459,511 shares of the company’s stock valued at $727,658,000 after purchasing an additional 2,186,114 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in Kenvue by 2.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 24,972,777 shares of the company’s stock valued at $533,169,000 after purchasing an additional 561,570 shares during the last quarter. 97.64% of the stock is owned by institutional investors.

Kenvue Price Performance

Shares of NYSE KVUE opened at $23.34 on Friday. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $24.46. The stock’s 50 day moving average price is $22.08 and its 200-day moving average price is $22.43. The company has a market capitalization of $44.61 billion, a PE ratio of 44.04, a PEG ratio of 2.62 and a beta of 1.25. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. On average, equities analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were paid a $0.205 dividend. The ex-dividend date of this dividend was Wednesday, February 12th. This represents a $0.82 annualized dividend and a yield of 3.51%. Kenvue’s payout ratio is 154.72%.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Piper Sandler lifted their price target on Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a research note on Monday, February 24th. Deutsche Bank Aktiengesellschaft downgraded Kenvue from a “buy” rating to a “hold” rating and cut their price target for the company from $25.00 to $24.00 in a research note on Thursday, December 12th. UBS Group cut their price target on Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a research note on Friday, February 7th. Royal Bank of Canada reiterated a “sector perform” rating and set a $24.00 price target on shares of Kenvue in a research note on Monday, February 3rd. Finally, Citigroup cut their price target on Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a research note on Wednesday, January 15th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, Kenvue has an average rating of “Hold” and a consensus target price of $23.75.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.